| Drug General Information |
| Drug ID |
D06ANS
|
| Former ID |
DIB014333
|
| Drug Name |
CVBT-141H
|
| Synonyms |
CVBT-141A; CVBT-141C; CVBT-141C); Cardio Vascu-Grow; FGF-1-141; Recombinant FGF-1 (coronary heart disease), CardioVascular Therapeutics; Recombinant FGF-1 (peripheral vascular disease), CardioVascular biotherapeutics
|
| Indication |
Coronary artery disease [ICD9: 410-414, 429.2; ICD10:I20-I25]
|
Phase 2 |
[1]
|
|---|
| Company |
CardioVascular BioTherapeutics Inc; CardioVascular Biotherapeutics
|
| Target and Pathway |
| Target(s) |
Heparin-binding growth factor1 |
Target Info |
Modulator |
[2]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Hippo signaling pathway
|
|
Regulation of actin cytoskeleton
|
|
Pathways in cancer
|
|
Melanoma
|
|
PANTHER Pathway
|
Angiogenesis
|
|
FGF signaling pathway
|
|
Pathway Interaction Database
|
FGF signaling pathway
|
|
Reactome
|
PI3K Cascade
|
|
PIP3 activates AKT signaling
|
|
FGFR4 ligand binding and activation
|
|
FGFR3c ligand binding and activation
|
|
FGFR2c ligand binding and activation
|
|
FGFR2b ligand binding and activation
|
|
FGFR3 mutant receptor activation
|
|
Activated point mutants of FGFR2
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
Phospholipase C-mediated cascade: FGFR1
|
|
Phospholipase C-mediated cascade
|
|
Phospholipase C-mediated cascade
|
|
Phospholipase C-mediated cascade
|
|
SHC-mediated cascade:FGFR1
|
|
PI-3K cascade:FGFR1
|
|
FRS-mediated FGFR1 signaling
|
|
PI-3K cascade:FGFR2
|
|
SHC-mediated cascade:FGFR2
|
|
FRS-mediated FGFR2 signaling
|
|
SHC-mediated cascade:FGFR3
|
|
FRS-mediated FGFR3 signaling
|
|
PI-3K cascade:FGFR3
|
|
FRS-mediated FGFR4 signaling
|
|
SHC-mediated cascade:FGFR4
|
|
PI-3K cascade:FGFR4
|
|
Negative regulation of FGFR1 signaling
|
|
Negative regulation of FGFR2 signaling
|
|
Negative regulation of FGFR3 signaling
|
|
Negative regulation of FGFR4 signaling
|
|
RAF/MAP kinase cascade
|
|
WikiPathways
|
Regulation of Actin Cytoskeleton
|
|
Differentiation Pathway
|
|
Hair Follicle Development: Organogenesis (Part 2 of 3)
|
|
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
|
|
PIP3 activates AKT signaling
|
|
Integrated Pancreatic Cancer Pathway
|
|
Signaling by FGFR
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020529) |
|---|
| REF 2 | Clinical pipeline report, company report or official report of CVBT. |
|---|
